Skip to main content
Premium Trial:

Request an Annual Quote

Sharp Edge Snags $156K Grant for Biosensor Technology Development

NEW YORK (GenomeWeb News) – Sharp Edge Labs announced on Monday it has been awarded a $156,000 Phase 1 Small Business Innovation Research grant to develop biosensor technology.

The grant from the National Institutes of Health and the National Cancer Institute will be used to develop biosensor technology for measuring the levels of molecules involved in cancer. Specifically, the Pittsburgh-based firm will explore the feasibility of developing immunosensors that combine antibodies for specific recognition with its Fluorogen Activating Peptide technology that generates a signal upon binding.

FAP is exclusively licensed by Sharp Edge. The technology was invented by the firm's co-founders Alan Waggoner and Marcel Bruchez, both professors at Carnegie Mellon University.

Scott Sneddon, president and CEO of Sharp Edge and principal investigator on the grant, said that in the current state of technology, each biosensor recognizes only very specific molecules. As a result, each sensor needs to be designed from the ground up, a costly and time-consuming process. Sharp Edge aims to develop biosensors that can recognize numerous molecules with its new antibody-FAP technology.

"The technology to be developed under this grant will simplify antibody assay procedures, increase the selectivity of existing antibodies, and provide sensors that can be 'multiplexed' allowing several different molecules to be detected simultaneously," Sneddon said in a statement. "We expect that this technology will have immediate application in the research laboratory and could eventually be used in clinical applications, especially point of care and patient self-testing."

The focus of the Phase 1 project is on a prototype for probing p53 activation states and HER-n complex formation, which are crucial in understanding cancer. Sharp Edge said that if the approach proves successful, the technology could be adapted for other disease areas, diagnostic settings, and the research lab.

Sharp Edge is privately held and was founded in 2010.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.